Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/86289
Type: Artigo de periódico
Title: We Know How To Prescribe Natalizumab For Multiple Sclerosis, But Do We Know How To Withdraw It?
Author: Fragoso Y.D.
Arruda N.M.
Arruda W.O.
Brooks J.B.B.
Correa E.C.
Damasceno A.
Damasceno C.A.
Ferreira M.L.B.
Giacomo M.C.B.
Gomes S.
Goncalves M.V.M.
Grzesiuk A.K.
Kaimen-Maciel D.R.
Lopes J.
Machado S.C.N.
Oliveira C.L.S.
Stella C.R.A.V.
Abstract: Natalizumab is a potent immunosuppressive monoclonal antibody used for the treatment of multiple sclerosis (MS). While definite guidelines for the safety of natalizumab prescriptions are available in all countries, there are no specific recommendations on how to withdraw the drug if the need arises. There are reports describing MS complications after natalizumab infusions were stopped. Most neurologists seem to stop natalizumab treatment according to their idea on how to best carry out the withdrawal. The present study shows the very different manners in which expert neurologists from 14 MS units in Brazil stopped natalizumab in their patients. The authors concluded that pharmacovigilance on natalizumab must persist after the drug is withdrawn in order to have enough data for adequate recommendations. © 2014 Informa UK, Ltd.
Editor: 
Rights: fechado
Identifier DOI: 10.1586/14737175.2014.874947
Address: http://www.scopus.com/inward/record.url?eid=2-s2.0-84893060675&partnerID=40&md5=def18976aa18d4765c17f7a3611f2bf6
Date Issue: 2014
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.